FDA panel to discuss Daiichi Sankyo's Savaysa

FDA's Cardiovascular and Renal Drugs advisory committee will meet on Oct. 30 to discuss an NDA from Daiichi Sankyo Co. Ltd. (Tokyo:4568) for Savaysa edoxaban to prevent stroke and systemic embolic events in patients with non-valvular atrial fibrillation (AF); to treat deep vein thrombosis (DVT) or pulmonary embolism (PE); and to prevent recurrence of symptomatic venous thromboembolism (VTE). ...